Efficacy of prolonged-release melatonin versus placebo in a three-week treatment of diabetic patients suffering from insomnia

Completed

• Conditions: Type 2 diabetes mellitus, insomnia; Nervous System Diseases; Sleep disorders

• Registration Number: ISRCTN55944464
• Lead Sponsor: eurim Pharmaceuticals Ltd. (Israel)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-02-27
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Independently living male and female patients (no age limits) who complained of insomnia and suffer from diabetes.

Exclusion Criteria

Patients with liver or renal problems (serum creatinine above 1.5 mg/dL).

Study & Design

• Study Type: Interventional
• Study Design: Not specified